# Merck & Co., Inc. (MRK) · Edgar & Edgarette company card

> Merck & Co. (MRK) grew revenue 1.3% in FY2025 to $65.0 billion, equity 38.4% of assets, and dividend per share up 15 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 310158 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/MRK) · [JSON](https://www.pops4.com/boards/company/MRK.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $65.0B |
| Revenue growth, 1 year | 1.3% |
| Revenue growth per year | 7.5% |
| Operating margin | — |
| Net margin | 28.1% |
| Operating cash flow | $16.5B |
| Capital spending | $4.1B |
| Free cash flow | $12.4B |
| Cash | $14.6B |
| Long-term debt | $49.3B |
| Total assets | $136.9B |
| Total equity | $52.6B |
| Equity ÷ assets | 38.4% |
| Return on equity | 34.7% |
| Dividend per share | $3.28 |
| Dividend years rising | 15 |

## Readings, computed from those figures

- Piotroski F: 4 of 9 (middling)
- Beneish M: -2.28 (below the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · slow and jumpy: growing slower than its size class, with revenue that swings more
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $65.0B (FY2025), total debt $49.3B. Experience: revenue up 1.3% on the year, up 7.5% a year over 4 years. Soundness: equity 38.4% of assets, return on equity 34.7%, payout 44.8% of profit, dividend per share up 15 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $57.8B and $71.3B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $52.7B to $77.6B. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): growth 1.3% against 13.7%.

Range logged 2026-09-26, receipt 61dd76eb71976daf, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-10-13 ([filing](https://www.sec.gov/Archives/edgar/data/310158/000031015826000237/0000310158-26-000237-index.htm))

## Recent filings

- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/0000310158-26-000248-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/0001104659-26-119825-index.htm)
- 8-K · filed 2026-10-13 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/310158/000031015826000237/0000310158-26-000237-index.htm)
- 10-Q · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/0000310158-26-000212-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/0001104659-26-090045-index.htm)
- 8-K · filed 2026-05-28 · 5.07 Submission of Matters to a Vote of Security Holders · [filing](https://www.sec.gov/Archives/edgar/data/310158/000110465926067509/0001104659-26-067509-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000310158.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=310158

## Cite

POPS4, Edgar & Edgarette: Merck & Co., Inc. (MRK) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/MRK. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.